Emergent BioSolutions CEO awarded 187,708 RSUs

Emergent BioSolutions President and CEO Joseph C. Papa received a grant of 187,708 restricted stock units, approved by the Compensation Committee and stockholders under the company’s Amended Stock Incentive Plan.

Rhea-AI Filing Summary

Emergent BioSolutions President and CEO Joseph C. Papa received a grant of 187,708 restricted stock units, approved by the Compensation Committee and stockholders under the company’s Amended Stock Incentive Plan. This equity award is a form of non-cash compensation and brings his direct holdings to 493,153 common shares.

The RSUs vest in three equal annual installments beginning on the anniversary of the approval date, assuming he continues serving at the company. Each restricted stock unit converts into one share of Emergent BioSolutions common stock upon vesting, aligning a portion of his compensation with future company performance.

Insider Trade Summary

Grant/Award: 187,708 shares

Grant/Award 1 txn

Insider PAPA JOSEPH C

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	187,708	$0.00	$0.00

Holdings After Transaction: Common Stock — 493,153 shares (Direct)

Footnotes (2)

1. F1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
2. F2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Key Figures

RSUs granted: 187,708 units Shares held after grant: 493,153 shares Grant price per share: $0.00 per share +2 more

5 metrics

RSUs granted 187,708 units Restricted stock units granted to CEO on award approval

Shares held after grant 493,153 shares CEO direct common stock holdings following RSU award

Grant price per share $0.00 per share Equity compensation, no cash paid by CEO for units

Vesting schedule 3 annual installments RSUs vest annually beginning on anniversary of approval date

Plan approval date April 29, 2026 Stockholders approved Amended Stock Incentive Plan

Key Terms

restricted stock units, Amended Stock Incentive Plan, Compensation Committee

3 terms

restricted stock units financial

"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended Stock Incentive Plan financial

"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")"

Compensation Committee financial

"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emergent BioSolutions (EBS) disclose in this Form 4 for its CEO?

Emergent BioSolutions reported that President and CEO Joseph C. Papa received 187,708 restricted stock units as equity compensation, increasing his direct common stock holdings to 493,153 shares after the award, under the company’s Amended Stock Incentive Plan approved by stockholders.

How many Emergent BioSolutions (EBS) RSUs were granted to CEO Joseph Papa?

Joseph C. Papa was granted 187,708 restricted stock units. These RSUs were approved under Emergent BioSolutions’ Amended Stock Incentive Plan and represent a right to receive an equal number of common shares as they vest, subject to continued service.

How and when do the CEO’s Emergent BioSolutions (EBS) RSUs vest?

The restricted stock units granted to the CEO vest in three equal annual installments. Vesting begins on the anniversary of the approval date, provided he continues serving with Emergent BioSolutions, gradually converting into common shares over that three-year period.

Was the CEO’s Emergent BioSolutions (EBS) RSU grant subject to stockholder approval?

Yes. The RSU grant was approved by the Compensation Committee on March 2, 2026, but was subject to stockholder approval of the Amended Stock Incentive Plan, which Emergent BioSolutions’ stockholders subsequently approved on April 29, 2026.

What is Joseph Papa’s total Emergent BioSolutions (EBS) share ownership after this grant?

Following the RSU award, Joseph C. Papa beneficially holds 493,153 shares of Emergent BioSolutions common stock directly. This figure reflects his position after the 187,708 restricted stock units were granted under the company’s Amended Stock Incentive Plan.

What does each Emergent BioSolutions (EBS) restricted stock unit granted to the CEO represent?

Each restricted stock unit represents the right to receive one share of Emergent BioSolutions common stock. Delivery occurs as units vest over three years, with the number of shares also subject to any adjustments described in the applicable grant agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAPA JOSEPH C

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026	04/29/2026(1)	A		187,708(2)	A	$0	493,153	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)